Skip to main content

Table 7 Health technology assessment information deemed to be important by stakeholders by stakeholder category (scale responses: 1 = strongly disagree; 7 = strongly agree)

From: Similarities and differences between stakeholders’ opinions on using Health Technology Assessment (HTA) information across five European countries: results from the EQUIPT survey

  Decision-maker Purchaser of services/pharma products Professional service provider Evidence generator Advocate of health promotion Total Kruskal–Wallis test
Statements n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) P value
Prevalence of smoking 29 5.66 (2.01) 7 6.71 (0.49) 18 6.33 (1.28) 25 5.84 (1.72) 14 5.57 (1.70) 93 5.90 (1.69) 0.43
Costs of smoking 29 6.55 (0.83) 7 6.71 (0.76) 18 6.61 (0.78) 25 6.36 (1.32) 14 6.50 (0.65) 93 6.52 (0.94) 0.81
Quality of life 29 6.17 (0.85) 7 6.14 (1.22) 18 5.61 (1.58) 25 5.64 (1.66) 14 5.64 (1.69) 93 5.84 (1.40) 0.76
Mortality due to smoking 29 6.59 (0.98) 7 6.57 (0.79) 18 6.33 (1.03) 25 6.20 (1.50) 14 5.71 (2.09) 93 6.30 (1.35) 0.68
Effectiveness of smoking cessation interventions (such as quit and relapse rates) 29 6.59 (0.83) 7 6.71 (0.76) 18 6.56 (1.20) 25 6.12 (1.76) 14 6.29 (1.59) 93 6.42 (1.31) 0.76
Cost-effectiveness data comparing the cost of smoking cessation interventions with its health and wider benefits 29 6.66 (0.48) 7 6.86 (0.38) 18 6.33 (0.97) 25 6.52 (0.82) 14 6.57 (0.85) 93 6.56 (0.74) 0.65
Budget impact reflecting financial outcomes specifically at organisational level 29 6.17 (1.39) 7 6.57 (0.56) 18 6.33 (0.97) 25 6.20 (1.19) 14 6.36 (0.93) 93 6.27 (1.13) 0.99
  1. SD, Standard deviation